Thus, by locally depleting multiple immunosuppressor cell types and significantly increasing CD8+ effector T cells in tumors, the CD73-targeted NIR-PIT + anti-PD1 antibody combination treatment could overcome acquired resistance to PD-1 blockade, and eradicate advanced tumor xenografts in mice, irrespective of CD73 expression levels in tumor cells 77. Here, PDCD1 is linked to neoplasm.